Published by Josh White on 20th March 2018
(ShareCast News) - Clinical stage biotechnology company ValiRx announced on Tuesday that the US patent and trademark office has granted the patent application 14/575065 (Anti-Androgen Peptides and Uses Thereof in Cancer Therapy), covering ValiRx's lead therapeutic compound, VAL201, which is in clinical trials.